RE:RE:Disappointing response by the market chrispi is right. This matters to companies interested in MS, but what everyone else hears is that xb3 works in rodents. Well, we knew that. What will move us is clinical news, or at least news that xb3 works in primates. We have to follow the long term plan; find partners and keep cash in the bank. Our day will come.
chrispi wrote: Sometimes it takes more than 1.5 hours for people to digest the news ;) ... especially during the summer holiday season. But more importantly than the market realizing, or not, the importance and significance of this successful study, is that our current and future partners are now aware of it. That will help licensing negotiations with current and future partners!